Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Susan Frances Lasserre"'
Autor:
Joy Mangel, Michael Crump, Gregg Fine, Susan Frances-Lasserre, Sarit Assouline, Douglas A. Stewart, Laurie H. Sehn, David Carlile, Randy D. Gascoyne
Publikováno v:
Blood. 119:5118-5125
This phase 1 study evaluated the safety, tolerability, pharmacokinetics, and antitumor activity of obinutuzumab (GA101), a glycoengineered type II anti-CD20 monoclonal antibody administered as induction followed by 2 years of maintenance. Cohorts of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c5dc2cb3d62643250ec2701ed487b43
https://doi.org/10.1182/blood-2012-02-408773
https://doi.org/10.1182/blood-2012-02-408773
Autor:
Jason E. Faris, Eli L. Diamond, Martina Makrutzki, Vivek Subbiah, Antoine Hollebecque, Maria Luisa Veronese, Maria Elena Elez-Fernandez, David M. Hyman, Radj Gervais, Juergen Wolf, Josep Tabernero, Igor Puzanov, Susan Frances Lasserre, Noopur Raje, Martin Schuler, Jean-Yves Blay, José Baselga, Emily Chan, Ian Chau, Ralf-Dieter Hofheinz, Florin Sirzen, Manuel Hidalgo, Antoine Italiano
BackgroundBRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–positive nonmelanoma cancers. MethodsWe enrolled patients in six prespecified c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db07b26d091caa624e875997ead64da8
http://europepmc.org/articles/pmc4971773
http://europepmc.org/articles/pmc4971773
